CROI 2017: Triple Tuberculosis Regimen Beats XDR-TB in First Trial


A regimen of three oral drugs given for 6 months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Francesca Conradie of Sizwe Tropical Disease Hospital in Johannesburg reported at the 2017 Conference on Retroviruses and Opportunistic Infections last week in Seattle. If the results are replicated in a larger population, the findings could revolutionize the prospects for treating not just XDR-TB, but also more severe cases of multidrug-resistant tuberculosis (MDR-TB).

XDR-TB is a growing problem in countries with a high burden of MDR-TB, such as South Africa. XDR-TB is TB that is resistant to isoniazid and rifampicin, plus any fluoroquinolone and at least 1 of 3 injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). MDR-TB is TB that is resistant to isoniazid and rifampicin.

XDR-TB Transmission

Although XDR-TB may be a consequence of failure of previous treatment for MDR-TB, research in South Africa has shown that transmission between people, often outside the household, is the primary driver of the country’s growing XDR-TB crisis. Furthermore, research presented this week at CROI shows that migration and travel plays a big part in the spread of XDR-TB in South Africa’s most severely affected province, KwaZulu-Natal.

Kristin Nelson of Emory University in Atlanta shared results of a study which sought to identify the geographical locations of individuals with genetically-linked XDR-TB infections. The study was designed to determine whether particular locations were strongly implicated in the spread of XDR-TB.

Surprisingly, the researchers found that the median distance between the homes of people in these genetically linked pairs was 111 km, and 83% of people in genetically linked pairs lived in different districts of the province. A very high level of mobility for work, for health care seeking, and for family reasons appears to be contributing to the spread of XDR-TB. Household transmission, traditionally considered to be the most important arena of TB transmission and the focus of contact tracing and case-finding efforts, appears to be less important than previously assumed.

XDR-TB Treatment

Current treatment for XDR-TB requires the assembly of a regimen of 6 drugs, including a 6-month phase of treatment that includes injectable drugs, and a further 12-18 months of treatment with 5 drugs. Some of the drugs used in the treatment of MDR-TB and XDR-TB have serious side effects, including hearing loss and kidney damage in the case of several injectable drugs. Some drugs used in the regimen are costly and unavailable in some countries, further complicating the construction of an effective regimen.

Even if people gain access to XDR-TB treatment and are able to tolerate the regimen, the cure rate is shockingly low. Follow-up of people treated for XDR-TB in South Africa between 2008 and 2012 shows that just 11% had been cured 5 years after beginning treatment, whereas 73% had died. Finding a shorter-duration regimen that is effective against XDR-TB with fewer serious side effects would greatly improve the chances of treating the infection and stopping onward transmission.

The NIX-TB study is testing a 3-drug regimen consisting of bedaquiline (Sirturo) -- the first new TB drug to be approved in 40 years -- linezolid (a cheap antibiotic), and pretomanid (PA-824), an experimental TB drug being developed by the TB Alliance. Francesca Conradie presented results on the first 72 people to be treated in the study.

Participants were eligible to join the study if they had documented XDR-TB, or were intolerant to an MDR-TB regimen and remained culture-positive, or were not cured by MDR-TB treatment and remained culture-positive. The study excluded people with HIV who had a CD4 cell count below 50 cells/mm3, and people with cardiac arrhythmia or severe peripheral neuropathy.

Of the 72 participants, 51% were HIV-positive, 65% had XDR-TB, 24% had MDR-TB treatment failure, and 11% were intolerant of MDR-TB treatment. The participants were fairly evenly divided by sex (54% male) and were predominantly black (78%).

Treatment is ongoing for some participants, so participant disposition is as follows:

  • 72 people initiated treatment;
  • 4 people died during treatment (3 due to disseminated TB and 1 due to gastrointestinal bleeding);
  • 28 people are still undergoing treatment;
  • 40 people have completed a 6-month course of treatment;
  • Of these, 31 people have completed treatment and 6 months of post-treatment follow-up.

Of the 31 who have completed post-treatment follow-up, 29 people cleared XDR-TB. One person has been reinfected with drug-susceptible TB. Another person appears to have suffered a relapse of XDR-TB, but genome sequencing is needed to determine whether this is a true case of relapse or whether it is a reinfection.

Culture conversion was uniformly rapid for a population with drug-resistant TB. All participants were culture negative within 4 months of starting treatment, and 26 of the 40 people who have completed treatment were culture negative by week 8 of treatment.

Adverse events during treatment were chiefly attributable to linezolid, and 49 of the 60 people who have undergone treatment to date have interrupted linezolid dosing at least once. In 14 cases the dose interruption was due to myelosuppression and in 28% the dose interruption was due to peripheral neuropathy.

Conradie said that peripheral neuropathy could be managed with gabapentine, but that it gradually diminishes after treatment is completed.



F Conradie, AH Diacon, D Everitt, et al. The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR-TB. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 80LB.

KN Nelson, NR Gandhi, SC Auld, et al. Whole-genome sequencing and spatial analysis of XDR-TB transmission in South Africa. Conference on Retroviruses and Opportunistic Infections. Seattle, February 13-16, 2017. Abstract 77.